![](/wp-content/uploads/2022/10/October-18-2022-Blast-Cover.png)
$599
Medtronic Launches 770G Personalized Insights Program; GSK Initiates Ph2b NASH Trial; J&J Q3 ’22 Earnings Update
Three cardiometabolic-related news items have been observed: Medtronic announced the launch of a new personalized program, called My Insights, which is designed to support patients using the MiniMed 770G AID system (view website); a new GSK-sponsored Ph2b trial (HORIZON) has been observed evaluating GSK4532990 (HSD17B13 silencer) in adults with NASH (view CT.gov record); and J&J hosted their Q3 ‘22 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective new items.